Clinical Trial Update: Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1 [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1/2 clinical trial evaluating ARO-DUX4 in adults and adolescents with facioscapulohumeral muscular dystrophy type 1. The study is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Facioscapulohumeral Muscular Dystrophy
• Facioscapulohumeral Muscular Dystrophy Type

Drugs mentioned

• ARO-DUX4 (antisense oligonucleotide targeting DUX4)

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Facio-Scapulo-Humeral Dystrophy | Phase 1, Phase 2 | Status: RECRUITING